Gilead Sciences, Inc. (GILD) Position Raised by Knott David M

Knott David M grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 30.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,720 shares of the biopharmaceutical company’s stock after buying an additional 1,550 shares during the period. Knott David M’s holdings in Gilead Sciences were worth $456,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Abner Herrman & Brock LLC raised its holdings in shares of Gilead Sciences by 0.5% in the first quarter. Abner Herrman & Brock LLC now owns 10,202 shares of the biopharmaceutical company’s stock worth $693,000 after buying an additional 50 shares during the last quarter. ARS Investment Partners LLC raised its holdings in shares of Gilead Sciences by 0.9% in the first quarter. ARS Investment Partners LLC now owns 5,610 shares of the biopharmaceutical company’s stock worth $381,000 after buying an additional 50 shares during the last quarter. Blue Fin Capital Inc. raised its holdings in shares of Gilead Sciences by 0.8% in the first quarter. Blue Fin Capital Inc. now owns 7,213 shares of the biopharmaceutical company’s stock worth $489,000 after buying an additional 55 shares during the last quarter. McKinley Carter Wealth Services Inc. raised its holdings in shares of Gilead Sciences by 1.3% in the first quarter. McKinley Carter Wealth Services Inc. now owns 4,986 shares of the biopharmaceutical company’s stock worth $339,000 after buying an additional 63 shares during the last quarter. Finally, Searle & CO. raised its holdings in shares of Gilead Sciences by 0.6% in the first quarter. Searle & CO. now owns 13,350 shares of the biopharmaceutical company’s stock worth $907,000 after buying an additional 80 shares during the last quarter. 74.05% of the stock is owned by institutional investors and hedge funds.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the sale, the insider now owns 3,199,969 shares of the company’s stock, valued at $227,197,799. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Robin L. Washington sold 51,820 shares of the stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the completion of the sale, the chief financial officer now directly owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The disclosure for this sale can be found here. Insiders sold 466,819 shares of company stock worth $36,740,240 in the last 90 days. 1.30% of the stock is currently owned by insiders.

A number of research firms have recently weighed in on GILD. BidaskClub lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Deutsche Bank AG reiterated a “buy” rating and issued a $81.00 price objective (up previously from $79.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Royal Bank Of Canada began coverage on shares of Gilead Sciences in a research note on Thursday. They issued an “outperform” rating and a $94.00 price objective on the stock. Zacks Investment Research lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Monday. Finally, TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Eleven investment analysts have rated the stock with a hold rating and twenty have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $83.79.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded up 0.50% on Friday, hitting $82.70. 7,655,198 shares of the company were exchanged. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The firm has a market cap of $108.00 billion, a P/E ratio of 8.98 and a beta of 1.19. The company has a 50-day moving average price of $76.95 and a 200 day moving average price of $70.12.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The firm had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. During the same quarter last year, the firm posted $3.08 earnings per share. Gilead Sciences’s revenue for the quarter was down 8.2% compared to the same quarter last year. Analysts predict that Gilead Sciences, Inc. will post $8.75 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be issued a $0.52 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 annualized dividend and a yield of 2.53%. Gilead Sciences’s payout ratio is 22.58%.

WARNING: This article was posted by BBNS and is the sole property of of BBNS. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://baseballnewssource.com/markets/gilead-sciences-inc-gild-position-raised-by-knott-david-m/1605226.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Los Angeles Dodgers Waiting But Magic Number Down to One
Los Angeles Dodgers Waiting But Magic Number Down to One
Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game


Leave a Reply

 
© 2006-2017 BBNS.